Group 1 - Zelluna ASA has issued 227,096 new shares as part of a resolution by its Board of Directors to set off an option exercise fee [1] - The new share capital of Zelluna ASA is now registered at NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1 [1] Group 2 - Zelluna ASA aims to provide transformative treatments for advanced solid cancers through innovative "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies [2] - The TCR-NK platform is designed to offer broad cancer detection capabilities, addressing the diversity of tumors and overcoming scaling limitations of current cell therapies [2] - The lead program targets MAGE-A4 and is the world's first "off the shelf" TCR-NK therapy for various solid cancers, with additional products in the pipeline [2] - The management team consists of biotech entrepreneurs with extensive experience in the discovery and clinical development of TCR and cell-based therapies [2]

Core Points - Zelluna ASA's Annual General Meeting authorized the Board of Directors to issue new shares at a subscription price of NOK 26 to settle an option exercise fee of EUR 500,000 to Inven2 [1] - The Board has resolved to issue 227,096 new shares to Inven2 in exchange for the aforementioned amount [1] Company Overview - Zelluna ASA aims to provide transformative treatments for advanced solid cancers in a safe and cost-efficient manner globally [2] - The company focuses on developing "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies, which offer a unique mechanism of action for broad cancer detection [2] - The lead program targets MAGE-A4 with the world's first "off the shelf" TCR-NK therapy for various solid cancers, with additional products in the pipeline [2] - The management team consists of biotech entrepreneurs with extensive experience in the discovery and clinical development of TCR and cell-based therapies [2]

Core Viewpoint - Zelluna ASA, a company focused on allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, announced its first quarter 2025 results, highlighting significant advancements in its manufacturing process and financial performance [1][2]. Financial Update - Total operating expenses for Q1 2025 were MNOK 22.2 [5]. - The net negative cash flow from operations was MNOK 36.0 [5]. - Proceeds from equity issuance amounted to MNOK 51.7, while net cash acquired from the business combination was MNOK 92.3, leading to a net increase in cash and cash equivalents of MNOK 108.0 during Q1 2025 [5]. - Cash and cash equivalents stood at MNOK 135.3 as of March 31, 2025 [5]. - A reverse share split was executed on March 31, 2025, resulting in 20,227,066 outstanding shares, each with a par value of NOK 1 [5]. Business Development - Zelluna successfully completed a business combination with Ultimovacs ASA and Zelluna Immunotherapy AS, along with a private placement that raised gross proceeds of MNOK 51.7 [5]. - The company has developed, scaled, and automated its proprietary manufacturing process for TCR-NK cell therapies, which allows for the production of hundreds of doses from a single batch, enhancing scalability and cost efficiency [5][6]. - The lead program targets MAGE-A4 for the treatment of various solid cancers, marking a significant innovation in the TCR-NK therapeutic field [6].